ROBERT M DEMEESTER
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical ROYAL OAK, MI NPI 1336461748
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical MI Gilead Sciences, Inc. All categories
General Payments — all program years on this page
$26,646.57
- Category: General Payments
- Program years: PY2021–2024
- Record count: 161
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $13,232.12 across 57 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,920.00 | 3 |
| Travel and Lodging | $3,421.31 | 8 |
| Consulting Fee | $1,518.75 | 2 |
| Food and Beverage | $1,372.06 | 44 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $10,903.71 | 21 |
| Genmab U.S., Inc. | $860.20 | 3 |
| ABBVIE INC. | $750.00 | 1 |
| SOBI, INC | $151.93 | 4 |
| Daiichi Sankyo Inc. | $61.16 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $46.45 | 3 |
| Acerta Pharma LLC | $42.63 | 2 |
| Genentech USA, Inc. | $40.88 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $40.70 | 2 |
| PFIZER INC. | $36.44 | 2 |
| GlaxoSmithKline, LLC. | $31.63 | 2 |
| Acrotech Biopharma Inc. | $28.65 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $26.67 | 1 |
| Astellas Pharma US Inc | $26.29 | 1 |
| Immunocore Limited | $25.94 | 1 |
| BeiGene USA, Inc. | $23.04 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $22.62 | 1 |
| TAIHO ONCOLOGY, INC. | $22.00 | 1 |
| E.R. Squibb & Sons, L.L.C. | $20.08 | 1 |
| GENZYME CORPORATION | $19.91 | 1 |
| Rigel Pharmaceuticals, Inc. | $18.64 | 1 |
| Lilly USA, LLC | $17.21 | 1 |
| EISAI INC. | $15.34 | 1 |
By program year
Records — PY2024 (57)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.